Chicago Equity Partners LLC lifted its holdings in Regeneron (NASDAQ:REGN) by 265.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,095 shares of the biopharmaceutical company’s stock after buying an additional 4,425 shares during the quarter. Chicago Equity Partners LLC’s holdings in Regeneron were worth $2,099,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its stake in shares of Regeneron by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 307 shares in the last quarter. Pin Oak Investment Advisors Inc. purchased a new stake in shares of Regeneron in the fourth quarter valued at approximately $152,000. Advisory Services Network LLC boosted its stake in shares of Regeneron by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 266 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Regeneron in the fourth quarter valued at approximately $204,000. Finally, AE Wealth Management LLC purchased a new stake in shares of Regeneron in the fourth quarter valued at approximately $206,000. Hedge funds and other institutional investors own 66.55% of the company’s stock.

Shares of NASDAQ:REGN opened at $303.21 on Thursday. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.11. Regeneron has a 52-week low of $297.53 and a 52-week high of $301.70. The firm has a market capitalization of $33.34 billion, a PE ratio of 22.61, a P/E/G ratio of 1.11 and a beta of 1.44.

Regeneron (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.08 by ($0.41). Regeneron had a net margin of 23.54% and a return on equity of 29.92%. The company had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the company earned $2.92 earnings per share. The firm’s revenue was up 14.6% compared to the same quarter last year. equities analysts anticipate that Regeneron will post 17.2 EPS for the current fiscal year.

In other news, Director George L. Sing sold 7,000 shares of the company’s stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $285.29, for a total value of $1,997,030.00. Following the sale, the director now directly owns 127,772 shares in the company, valued at $36,452,073.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $350.02, for a total value of $700,040.00. Following the completion of the sale, the director now owns 14,000 shares in the company, valued at $4,900,280. The disclosure for this sale can be found here. Insiders sold 11,000 shares of company stock worth $3,377,070 over the last 90 days. Company insiders own 12.42% of the company’s stock.

A number of research firms recently weighed in on REGN. Jefferies Group restated a “hold” rating and issued a $421.00 price target on shares of Regeneron in a research note on Friday, February 2nd. Morgan Stanley lifted their price target on Regeneron from $401.00 to $415.00 and gave the company an “equal weight” rating in a research note on Friday, February 9th. BidaskClub downgraded Regeneron from a “sell” rating to a “strong sell” rating in a research note on Wednesday, May 9th. Guggenheim set a $530.00 price target on Regeneron and gave the company a “buy” rating in a research note on Friday, February 9th. Finally, Leerink Swann set a $435.00 price target on Regeneron and gave the company a “buy” rating in a research note on Friday, May 4th. Four analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company’s stock. Regeneron presently has an average rating of “Hold” and an average price target of $426.88.

About Regeneron

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Institutional Ownership by Quarter for Regeneron (NASDAQ:REGN)

Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.